Truist lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $13 and keeps a Hold rating on the shares after its Q3 results. The company’s Zurzuvae sales grew 48% sequentially as its launch is tracking well, and in a promotion-responsive market with broad coverage, the firm is constructive on the stock, the analyst tells investors in a research note. Truist notes however that Sage’s expenses are high with a Q3 cash burn of $82M, while the visibility into its cash runway “remains poor”.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $8 from $9 at Oppenheimer
- Sage Therapeutics price target lowered to $14 from $17 at Scotiabank
- Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
- Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright
- Sage Therapeutics Reports Q3 Growth and Strategic Focus